Named on one round in the feed.
Since 2025-05-13
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Azafaros Azafaros develops therapeutics for patients with rare metabolic disorders, particularly those affecting the lysosomal storage system. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $146.7M | 2025-05-13 | [ PART ] |